EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head

Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?

Detalles Bibliográficos
Autores principales: Clark, Jennifer, Cools, Jan, Gilliland, D. Gary
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2005
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549608/
https://www.ncbi.nlm.nih.gov/pubmed/15736989
http://dx.doi.org/10.1371/journal.pmed.0020075
_version_ 1782122446322663424
author Clark, Jennifer
Cools, Jan
Gilliland, D. Gary
author_facet Clark, Jennifer
Cools, Jan
Gilliland, D. Gary
author_sort Clark, Jennifer
collection PubMed
description Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
format Text
id pubmed-549608
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-5496082005-02-28 EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head Clark, Jennifer Cools, Jan Gilliland, D. Gary PLoS Med Perspectives Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance? Public Library of Science 2005-03 2005-02-22 /pmc/articles/PMC549608/ /pubmed/15736989 http://dx.doi.org/10.1371/journal.pmed.0020075 Text en Copyright: © 2005 Clark et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Perspectives
Clark, Jennifer
Cools, Jan
Gilliland, D. Gary
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title_full EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title_fullStr EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title_full_unstemmed EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title_short EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
title_sort egfr inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549608/
https://www.ncbi.nlm.nih.gov/pubmed/15736989
http://dx.doi.org/10.1371/journal.pmed.0020075
work_keys_str_mv AT clarkjennifer egfrinhibitioninnonsmallcelllungcancerresistanceonceagainrearsitsuglyhead
AT coolsjan egfrinhibitioninnonsmallcelllungcancerresistanceonceagainrearsitsuglyhead
AT gillilanddgary egfrinhibitioninnonsmallcelllungcancerresistanceonceagainrearsitsuglyhead

Ejemplares similares